Last reviewed · How we verify
Untreated hairy cell leukemia with active disease
Approved treatments
- Nipent · Pfizer Inc.
Clinical guidelines
- FDA label — 1L|2L
NIPENT is indicated as single-agent treatment for hairy cell leukemia patients with disease-related symptoms. - FDA label — 1L
NIPENT is indicated as single-agent treatment for untreated hairy cell leukemia patients with active disease. - FDA label — 2L
NIPENT is indicated as single-agent treatment for alpha-interferon-refractory hairy cell leukemia patients with active disease. - FDA label — 1L|2L
NIPENT is indicated as single-agent treatment for hairy cell leukemia patients with clinically significant anemia. - FDA label — 1L|2L
NIPENT is indicated as single-agent treatment for hairy cell leukemia patients with neutropenia. - FDA label — 1L|2L
NIPENT is indicated as single-agent treatment for hairy cell leukemia patients with thrombocytopenia.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Untreated hairy cell leukemia with active disease patent landscape — cliff calendar, originator estates, attackable patents
- Untreated hairy cell leukemia with active disease treatment landscape brief
- Untreated hairy cell leukemia with active disease treatment updates RSS
Frequently asked questions about Untreated hairy cell leukemia with active disease
What drugs treat Untreated hairy cell leukemia with active disease?
Tracked treatments include Nipent.
What is the treatment for Untreated hairy cell leukemia with active disease?
Standard treatment for Untreated hairy cell leukemia with active disease includes Nipent. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Untreated hairy cell leukemia with active disease?
FDA label publishes guidelines for Untreated hairy cell leukemia with active disease. 6 guideline references tracked.
Related
- Treatment landscape: Untreated hairy cell leukemia with active disease patent cliff · Untreated hairy cell leukemia with active disease CI report
- Treatment: Nipent · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing